SAN DIEGO, April 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, 2024.
On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Conference Call Details
The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, May 2, 2024. Interested parties may access the live teleconference through the Investor Info section of Illumina's website at investor.illumina.com. Alternatively, individuals can access the call by dialing 866.400.0049 or +1.323.701.0225 outside North America, both with Conference ID 9170634. To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.
A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube
Investors:
Salli Schwartz
+1.858.291.6421
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
David McAlpine
+1.347.327.1336
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$140.14 |
Daily Change: | 3.15 2.30 |
Daily Volume: | 1,919,548 |
Market Cap: | US$22.320B |
November 19, 2024 November 04, 2024 October 31, 2024 October 09, 2024 August 27, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB